IMI vs Illumina Which Is More Profitable?

IMI and Illumina are two prominent companies in the healthcare and biotechnology industries, with both companies being leaders in their respective fields. IMI focuses on medical devices and equipment, while Illumina specializes in genomic sequencing technology. Investors may be drawn to IMI for its innovative medical solutions and strong market presence, while Illumina's cutting-edge technology and industry partnerships make it a compelling choice for those looking to invest in the rapidly evolving field of genomics. This comparison will explore the key differences between the two companies and provide insights for potential investors.

IMI or Illumina?

When comparing IMI and Illumina, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between IMI and Illumina.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. IMI has a dividend yield of 1.66%, while Illumina has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. IMI reports a 5-year dividend growth of -7.81% year and a payout ratio of 29.10%. On the other hand, Illumina reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with IMI P/E ratio at 18.17 and Illumina's P/E ratio at -15.20. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. IMI P/B ratio is 4.21 while Illumina's P/B ratio is 9.88.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, IMI has seen a 5-year revenue growth of 0.20%, while Illumina's is 0.26%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with IMI's ROE at 23.85% and Illumina's ROE at -41.29%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are £1753.00 for IMI and $149.60 for Illumina. Over the past year, IMI's prices ranged from £1512.00 to £1911.00, with a yearly change of 26.39%. Illumina's prices fluctuated between $89.75 and $156.66, with a yearly change of 74.56%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.